Tela Bio Inc (TELA) - Net Assets
Based on the latest financial reports, Tela Bio Inc (TELA) has net assets worth $1.56 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($61.59 Million) and total liabilities ($60.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Tela Bio Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.56 Million |
| % of Total Assets | 2.53% |
| Annual Growth Rate | N/A |
| 5-Year Change | -41.95% |
| 10-Year Change | N/A |
| Growth Volatility | 46.36 |
Tela Bio Inc - Net Assets Trend (2017–2024)
This chart illustrates how Tela Bio Inc's net assets have evolved over time, based on quarterly financial data. Also explore Tela Bio Inc asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Tela Bio Inc (2017–2024)
The table below shows the annual net assets of Tela Bio Inc from 2017 to 2024. For live valuation and market cap data, see market value of Tela Bio Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $28.46 Million | +50.72% |
| 2023-12-31 | $18.88 Million | +31.99% |
| 2022-12-31 | $14.30 Million | -28.82% |
| 2021-12-31 | $20.10 Million | -59.01% |
| 2020-12-31 | $49.03 Million | +58.34% |
| 2019-12-31 | $30.96 Million | +122.46% |
| 2018-12-31 | $-137.86 Million | -27.45% |
| 2017-12-31 | $-108.17 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tela Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25055900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $39.00K | 0.14% |
| Other Comprehensive Income | $90.00K | 0.32% |
| Other Components | $387.06 Million | 1360.11% |
| Total Equity | $28.46 Million | 100.00% |
Tela Bio Inc Competitors by Market Cap
The table below lists competitors of Tela Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ENERSIDE ENERGY EO -01
F:9O8
|
$39.43 Million |
|
Daewon Co. Ltd
KQ:007680
|
$39.43 Million |
|
Dancomech Holdings Bhd
KLSE:5276
|
$39.44 Million |
|
Changchai Co Ltd
SHE:200570
|
$39.45 Million |
|
Chia Ta World Co Ltd
TW:2033
|
$39.41 Million |
|
Prefab Bucures
RO:PREH
|
$39.41 Million |
|
Rightmove PLC
LSE:RMV
|
$39.40 Million |
|
Jubilee Enterprise Public Company Limited
BK:JUBILE
|
$39.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tela Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 18,881,000 to 28,458,000, a change of 9,577,000 (50.7%).
- Net loss of 37,841,000 reduced equity.
- New share issuances of 42,919,000 increased equity.
- Other comprehensive income decreased equity by 1,000.
- Other factors increased equity by 4,500,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-37.84 Million | -132.97% |
| Share Issuances | $42.92 Million | +150.82% |
| Other Comprehensive Income | $-1.00K | -0.0% |
| Other Changes | $4.50 Million | +15.81% |
| Total Change | $- | 50.72% |
Book Value vs Market Value Analysis
This analysis compares Tela Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.99x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-16.67 | $0.99 | x |
| 2018-12-31 | $-21.25 | $0.99 | x |
| 2019-12-31 | $2.71 | $0.99 | x |
| 2020-12-31 | $3.79 | $0.99 | x |
| 2021-12-31 | $1.39 | $0.99 | x |
| 2022-12-31 | $0.88 | $0.99 | x |
| 2023-12-31 | $0.83 | $0.99 | x |
| 2024-12-31 | $1.00 | $0.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tela Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -132.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -54.60%
- • Asset Turnover: 0.79x
- • Equity Multiplier: 3.07x
- Recent ROE (-132.97%) is below the historical average (-123.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -502.57% | 0.27x | 0.00x | $-10.52 Million |
| 2018 | 0.00% | -254.92% | 0.30x | 0.00x | $-7.31 Million |
| 2019 | -72.43% | -145.18% | 0.23x | 2.19x | $-25.52 Million |
| 2020 | -58.73% | -158.10% | 0.21x | 1.76x | $-33.70 Million |
| 2021 | -165.57% | -112.94% | 0.47x | 3.11x | $-35.29 Million |
| 2022 | -309.65% | -106.95% | 0.61x | 4.74x | $-45.73 Million |
| 2023 | -247.15% | -79.83% | 0.75x | 4.13x | $-48.55 Million |
| 2024 | -132.97% | -54.60% | 0.79x | 3.07x | $-40.69 Million |
Industry Comparison
This section compares Tela Bio Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tela Bio Inc (TELA) | $1.56 Million | 0.00% | 38.55x | $39.41 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About Tela Bio Inc
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue… Read more